Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
|
BMJ
|
2002
|
20.22
|
2
|
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
|
N Engl J Med
|
2001
|
20.20
|
3
|
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
|
Eur Heart J
|
2012
|
18.18
|
4
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
|
N Engl J Med
|
2009
|
18.03
|
5
|
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
|
Lancet
|
1988
|
15.40
|
6
|
Risk of cardiovascular events associated with selective COX-2 inhibitors.
|
JAMA
|
2001
|
13.93
|
7
|
2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
|
Eur Heart J
|
2014
|
9.73
|
8
|
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
|
Lancet
|
2013
|
8.16
|
9
|
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
|
Lancet
|
2005
|
5.86
|
10
|
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
|
Lancet
|
2010
|
5.30
|
11
|
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
|
N Engl J Med
|
2005
|
5.28
|
12
|
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
|
Eur Heart J
|
2015
|
5.15
|
13
|
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
|
Circulation
|
2004
|
4.56
|
14
|
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
|
J Am Coll Cardiol
|
2013
|
3.05
|
15
|
Aspirin as an antiplatelet drug.
|
N Engl J Med
|
1994
|
2.72
|
16
|
The mechanism of action of aspirin.
|
Thromb Res
|
2003
|
2.72
|
17
|
24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease.
|
Thromb Haemost
|
2010
|
2.15
|
18
|
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
|
J Am Coll Cardiol
|
2007
|
2.01
|
19
|
Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions.
|
Am J Pathol
|
1999
|
2.00
|
20
|
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes.
|
J Thromb Haemost
|
2012
|
1.89
|
21
|
Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?
|
Heart
|
2010
|
1.57
|
22
|
The discovery of aspirin's antithrombotic effects.
|
Tex Heart Inst J
|
2007
|
1.45
|
23
|
Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin.
|
Stroke
|
1992
|
1.44
|
24
|
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system.
|
Proc Natl Acad Sci U S A
|
2012
|
1.35
|
25
|
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
|
Circulation
|
2011
|
1.33
|
26
|
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
|
J Am Coll Cardiol
|
2010
|
1.26
|
27
|
Enzyme immunoassays of eicosanoids using acetylcholinesterase.
|
Methods Enzymol
|
1990
|
1.15
|
28
|
In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.
|
J Thromb Haemost
|
2011
|
1.03
|
29
|
Risk factors for gastrointestinal bleeding associated with low-dose aspirin.
|
Best Pract Res Clin Gastroenterol
|
2012
|
1.02
|
30
|
Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.
|
Thromb Haemost
|
2001
|
1.01
|
31
|
Interaction of diuretics and non-steroidal anti-inflammatory drugs in man.
|
Clin Sci (Lond)
|
1983
|
1.01
|
32
|
Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin.
|
J Thromb Haemost
|
2006
|
0.99
|
33
|
Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.
|
Br J Clin Pharmacol
|
2011
|
0.99
|
34
|
Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial.
|
J Thromb Haemost
|
2015
|
0.99
|
35
|
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
|
Arterioscler Thromb Vasc Biol
|
2014
|
0.99
|
36
|
Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.
|
J Am Coll Cardiol
|
1999
|
0.96
|
37
|
Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction.
|
Arterioscler Thromb Vasc Biol
|
2015
|
0.89
|
38
|
High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells.
|
Biomed Res Int
|
2013
|
0.80
|
39
|
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
|
Am J Physiol Heart Circ Physiol
|
2007
|
0.79
|
40
|
Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1 alpha excretion in healthy subjects.
|
Thromb Res
|
1987
|
0.75
|